Armata Pharmaceuticals, Inc. 10-Qquarter ended 2026-06-30

Executive Summary

Armata Pharmaceuticals is advancing bacteriophage treatments for difficult bacterial infections, with AP-SA02 moving toward a planned Phase 3 trial after encouraging but small Phase 2 results and favorable regulatory feedback. The quarter delivered higher grant revenue, but development and corporate costs rose faster; a $91.0M noncash convertible-loan valuation gain turned a $10.3M operating loss into $74.1M of reported net income. A May borrowing extended the company’s cash resources, yet management says cash will not fund the 12 months following issuance of the financial statements and identifies substantial doubt about its ability to continue as a going concern. For investors, the opportunity is meaningful clinical progress, but financing terms and the ability to fund Phase 3 are more consequential than the quarter’s reported profit.

Key Financial Highlights

• Earnings quality: Q2 included a $91.0M noncash convertible-loan fair-value gain; H1 included a $10.0M loss on that liability. Despite Q2 basic EPS of $2.02, diluted EPS was $(0.27) after the if-converted calculation removed the gain and included conversion shares.
• Cash conversion: H1 operating cash flow was $(14.4)M vs a GAAP net loss of $(41.2)M; $0.080M of capital expenditures put free cash flow at $(14.5)M. Noncash debt interest and the convertible-loan valuation loss contributed to the gap between earnings and cash use.
• Funding and debt: H1 financing inflow was $28.5M, including a new $25.0M secured term loan and $2.37M of net share-sale proceeds. Convertible-loan carrying value was $164M and term-debt carrying value was $120M; H1 interest expense rose to $12.2M from $7.41M, including $12.2M of noncash interest.
• Compensation and issuance: H1 stock-based compensation rose to $4.47M from $1.4M. Shares outstanding increased from 36.4M at year-end to 37.1M at 6/30/2026, including 0.338M shares sold through the at-the-market program.

Business Developments

AP-SA02 is Armata’s clearest near-term development priority. In its Phase 2a S. aureus bacteremia study, investigator-assessed day-12 response was 88% with AP-SA02 plus antibiotics vs 58% with antibiotics plus placebo; the groups were small, with 24 and 12 assessed patients, respectively. The Food and Drug Administration advised that the data supported advancement to Phase 3, and AP-SA02 received Qualified Infectious Disease Product and Fast Track designations in 2026. Management planned a ≈450-patient Phase 3 trial for the second half of 2026; on 7/20/2026, Armata said it had submitted the protocol and completed four manufacturing engineering runs. The evidence supports further testing, not a conclusion that the larger trial will succeed.

The MTEC cost-reimbursement award for AP-SA02 increased by $2.5M to $28.7M and was extended through 9/30/2026. It helps fund preparation but does not eliminate the need for financing. AP-PA02’s Phase 2 bronchiectasis study produced favorable post-hoc pooled bacterial-count findings, while separate cohort analyses did not show a significant treatment difference; further development depends on funding or a partner. Management also reports manufacturing improvements intended to support intravenous dosing and eventual scale-up, while other pipeline opportunities remain funding-dependent.

Risk Assessment

• Going concern and liquidity: Management says cash will not cover the 12 months following issuance of the statements; without additional capital, Armata may delay or curtail programs, relinquish rights, or cease operations.
• Secured debt and refinancing: The $164M convertible-loan carrying value and $120M term-debt carrying value sit against $24.0M of cash and cash equivalents; secured claims, maturities and covenants constrain financing flexibility.
• Clinical execution: AP-SA02’s Phase 2 response advantage came from a small study, while a larger Phase 3 trial requires funding, manufacturing readiness and confirmation of efficacy.
• Dilution and financing terms: Shares outstanding increased during H1, and warrants, options and convertible-loan conversion shares create substantial additional dilution potential; a qualifying financing can trigger conversion at a discount.
• Valuation volatility: The convertible loan’s share-price-sensitive fair value produced a $91.0M Q2 gain but a $10.0M H1 loss, making GAAP net income an unreliable measure of operating progress.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

Armata’s investment case turns on converting AP-SA02’s Phase 2 and regulatory progress into a funded, executable Phase 3 program. MTEC support and new borrowing provide near-term resources, but neither resolves the going-concern warning; AP-PA02 partnerships offer a possible way to advance a second program without bearing its full cost.

• Phase 3 readiness: Monitor trial initiation, clinical-material production and financing; a funded start would validate the development timetable, while delay would weaken it.
• Liquidity: Monitor cash and cash equivalents against operating cash use, alongside any new debt or equity terms; financing that extends runway without sharply increasing claims or dilution would improve the investment case.
• Clinical evidence: Monitor whether subsequent AP-SA02 data confirm the Phase 2 response advantage and acceptable safety in a larger population.